Small Molecules
21 September 2015
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tofacitinib in Adults with Moderate-to-Severe Ulcerative Colitis21 September 2015
Tyrogenex Presents Final Results from Phase 1 Study of X-82 for Wet AMD at the 15th EURETINA Congress21 September 2015
MerLion’s Finafloxacin Shown to be More Efficacious than Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections20 September 2015
Cidara Therapeutics Presents Results from Key Studies Evaluating Its Novel Echinocandin CD101 at ICAAC/ICC 201520 September 2015
Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections20 September 2015
Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs19 September 2015
Summit Therapeutics Presents New Positive Preclinical Data on Novel C. difficile Antibiotic SMT19969 at ICAAC 201519 September 2015
TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination19 September 2015
The Medicines Company Reports Discovery of New Series of Beta-Lactamase Inhibitors at ICAAC/ICC 201519 September 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors19 September 2015
Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 201518 September 2015
Ignyta Announces Initiation of Phase 1/1b Clinical Trial of RXDX-10717 September 2015
Apricus Reports Top-Line Phase 2a Data for RayVa(TM), Its Topical Treatment for Raynaud’s Phenomenon17 September 2015
New data demonstrates Jardiance®▼ (empagliflozin) showed a significant reduction in cardiovascular risk in diabetes patients in a dedicated outcome trial17 September 2015
Ventrix Initiates Clinical Trial of VentriGel16 September 2015
Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis16 September 2015
Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and DepressionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports